Skip to content
ABOUT
Summary
Milestones
Our Team
Board
Scientific Advisory Board
Investors
SCIENCE
Summary
Pipeline
Publications and Abstracts
CLINICAL TRIALS
IN THE NEWS
CONTACT
Careers
ABOUT
Summary
Milestones
Our Team
Board
Scientific Advisory Board
Investors
SCIENCE
Summary
Pipeline
Publications and Abstracts
CLINICAL TRIALS
IN THE NEWS
CONTACT
Careers
In the News
August 28, 2023
ONL Therapeutics Completes Enrollment in Phase 2 Study of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
Read More
April 12, 2023
ONL Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
Read More
April 11, 2023
ONL Therapeutics to Report Clinical Data on ONL1204 in Podium Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Read More
March 8, 2023
ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial
Read More
February 13, 2023
ONL Therapeutics to Present at the XXVth Biennial Meeting of the International Society for Eye Research
Read More
February 2, 2023
ONL Therapeutics to Present at 2023 BIO CEO & Investor Conference
Read More
February 1, 2023
ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution
Read More
January 26, 2023
ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research
Read More
July 12, 2022
AmbioPharm Supports ONL Therapeutics with Peptide Manufacturing to Prepare for IND Application for Phase 2 Study
Read More
February 9, 2022
ONL Therapeutics Appoints Sushanta Mallick as Chief Development Officer
Read More
<
1
2
3
4
>